重药控股：第三季度归母净利润1.02亿元，同比增加87.94%

Core Viewpoint - The company reported a revenue of 21.023 billion yuan for Q3 2025, marking a year-on-year growth of 5.57% and a net profit attributable to shareholders of 102 million yuan, which represents a significant increase of 87.94% [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 62.211 billion yuan, reflecting a year-on-year growth of 4.22% [1] - The net profit attributable to shareholders for the same period was 384 million yuan, showing a year-on-year increase of 31.41% [1] - The basic earnings per share for Q3 2025 was reported at 0.06 yuan [1]